- Home
- HSII vs ETNB Comparison
HSII vs ETNB Comparison
Compare HSII & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- ETNB
- Stock Information
- Founded
- HSII 1953
- ETNB 2018
- Country
- HSII United States
- ETNB United States
- Employees
- HSII N/A
- ETNB N/A
- Industry
- HSII Diversified Commercial Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- ETNB Health Care
- Exchange
- HSII Nasdaq
- ETNB Nasdaq
- Market Cap
- HSII 904.3M
- ETNB 1.0B
- IPO Year
- HSII 1999
- ETNB 2019
- Fundamental
- Price
- HSII $42.35
- ETNB $7.70
- Analyst Decision
- HSII Buy
- ETNB Strong Buy
- Analyst Count
- HSII 2
- ETNB 9
- Target Price
- HSII $48.00
- ETNB $27.25
- AVG Volume (30 Days)
- HSII 139.5K
- ETNB 1.5M
- Earning Date
- HSII 05-05-2025
- ETNB 05-01-2025
- Dividend Yield
- HSII 1.42%
- ETNB N/A
- EPS Growth
- HSII N/A
- ETNB N/A
- EPS
- HSII 0.37
- ETNB N/A
- Revenue
- HSII $1,116,954,000.00
- ETNB N/A
- Revenue This Year
- HSII $1.86
- ETNB N/A
- Revenue Next Year
- HSII $3.66
- ETNB N/A
- P/E Ratio
- HSII $114.71
- ETNB N/A
- Revenue Growth
- HSII 6.10
- ETNB N/A
- 52 Week Low
- HSII $30.20
- ETNB $4.16
- 52 Week High
- HSII $49.02
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- HSII 61.05
- ETNB 53.47
- Support Level
- HSII $38.53
- ETNB $7.40
- Resistance Level
- HSII $41.12
- ETNB $8.92
- Average True Range (ATR)
- HSII 1.22
- ETNB 0.54
- MACD
- HSII 0.58
- ETNB 0.13
- Stochastic Oscillator
- HSII 68.80
- ETNB 53.88
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).